Viatris Inc.
VTRS
株式のランク
#1100
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
株価
$18.50
最終同期: 2026-10-20
時価総額
$21.24B
変化（1日）
1.29%
変化（1年）
78.01%
国
US
取引 Viatris Inc. (VTRS)
カテゴリー
Healthcare
Viatris Inc.（VTRS）の収益
Jun 2026 時点の収益 TTM: $14.74B
Viatris Inc. の最新の財務報告によると、現在の収益 (TTM) は $14.74B です。2023 年には $15.43B の収益があり、これは 2022 年の $16.26B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Viatris Inc. の収益履歴（2004 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $14.74B | -0.01% |
| 2024 | $14.74B | -4.46% |
| 2023 | $15.43B | -5.14% |
| 2022 | $16.26B | -9.08% |
| 2021 | $17.89B | 49.73% |
| 2020 | $11.95B | 3.87% |
| 2019 | $11.50B | 0.58% |
| 2018 | $11.43B | -3.98% |
| 2017 | $11.91B | 7.50% |
| 2016 | $11.08B | 17.47% |
| 2015 | $9.43B | 22.15% |
| 2014 | $7.72B | 11.73% |
| 2013 | $6.91B | 1.66% |
| 2012 | $6.80B | 10.87% |
| 2011 | $6.13B | 12.46% |
| 2010 | $5.45B | 7.02% |
| 2009 | $5.09B | -0.87% |
| 2008 | $5.14B | 76.85% |
| 2007 | $2.91B | 131.08% |
| 2006 | $1.26B | 0.30% |
| 2005 | $1.25B | -8.82% |
| 2004 | $1.37B | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | -55.14% |
IN
|
